ProAxsis is a medical diagnostics company spun-out from Queens University – Belfast, and developing a range of products for the capture, detection, and measurement of active protease biomarkers of diseases. NetScientific acquired minority interest in ProAxsis in October 2020, and is now a fully-owned subsidiary.
The rapid and easy-to-use tests ProAxsis has developed incorporate patented ProteaseTags®; smart molecules which trap an active protease within a complex biological sample and enable a visual readout of its presence.
The initial applications for the technology are focused on managing chronic respiratory diseases, Cystic Fibrosis (CF), and Chronic Obstructive Pulmonary Disease (COPD), where exacerbations have a major impact on the long-term prognosis of patients. There are 70,000 patients diagnosed with CF worldwide and 35.7m patients with COPD in the US and EU alone.